Neurological disorders,including headaches(tension-type headaches,medication-overuse headaches,and migraines)and dementias that include Alzheimer’s disease,are among the most prevalent and debilitating global conditi...Neurological disorders,including headaches(tension-type headaches,medication-overuse headaches,and migraines)and dementias that include Alzheimer’s disease,are among the most prevalent and debilitating global conditions.In 2016,these disorders affected 276 million people worldwide and were the second leading cause of death that year[1].This highlights the urgent need for effective prevention,treatment,and support strategies.The etiology of neurological disorders is multifaceted and involves genetic,environmental,physiological,and social factors[2].展开更多
Epigenetics is closely related to cardiovascular diseases.Genome-wide linkage and association analyses and candidate gene approaches illustrate the multigenic complexity of cardiovascular disease.Several epigenetic me...Epigenetics is closely related to cardiovascular diseases.Genome-wide linkage and association analyses and candidate gene approaches illustrate the multigenic complexity of cardiovascular disease.Several epigenetic mechanisms,such as DNA methylation,histone modification,and noncoding RNA,which are of importance for cardiovascular disease development and regression.Targeting epigenetic key enzymes,especially the DNA methyltransferases,histone methyltransferases,histone acetylases,histone deacetylases and their regulated target genes,could represent an attractive new route for the diagnosis and treatment of cardiovascular diseases.Herein,we summarize the knowledge on epigenetic history and essential regulatory mechanisms in cardiovascular diseases.Furthermore,we discuss the preclinical studies and drugs that are targeted these epigenetic key enzymes for cardiovascular diseases therapy.Finally,we conclude the clinical trials that are going to target some of these processes.展开更多
基金supported by the National Key Research and Development Program of China[2018YFE0206900].
文摘Neurological disorders,including headaches(tension-type headaches,medication-overuse headaches,and migraines)and dementias that include Alzheimer’s disease,are among the most prevalent and debilitating global conditions.In 2016,these disorders affected 276 million people worldwide and were the second leading cause of death that year[1].This highlights the urgent need for effective prevention,treatment,and support strategies.The etiology of neurological disorders is multifaceted and involves genetic,environmental,physiological,and social factors[2].
基金support by the National Key Research and Development Program[2020YFC2004405]National Natural Science Foundation of China(NSFC)[82073408]to JC,NSFC[82061160372 and 81870506]+4 种基金project of traditional Chinese medicine in Guangdong province[20201062]Basic Research Project of Shenzhen Science and Technology Innovation Committee[JCYJ20180306174648342 and JCYJ20190808102005602]Futian District Public Health Scientific Research Project of Shenzhen[FTWS2019003]Shenzhen Key Medical Discipline Construction Fund[SZXK002]Guangdong Basic and Applied Basic Research Foundation 2021B1515120083].
文摘Epigenetics is closely related to cardiovascular diseases.Genome-wide linkage and association analyses and candidate gene approaches illustrate the multigenic complexity of cardiovascular disease.Several epigenetic mechanisms,such as DNA methylation,histone modification,and noncoding RNA,which are of importance for cardiovascular disease development and regression.Targeting epigenetic key enzymes,especially the DNA methyltransferases,histone methyltransferases,histone acetylases,histone deacetylases and their regulated target genes,could represent an attractive new route for the diagnosis and treatment of cardiovascular diseases.Herein,we summarize the knowledge on epigenetic history and essential regulatory mechanisms in cardiovascular diseases.Furthermore,we discuss the preclinical studies and drugs that are targeted these epigenetic key enzymes for cardiovascular diseases therapy.Finally,we conclude the clinical trials that are going to target some of these processes.
